GSK2838232

InvivoChem Cat #:V3600CAS #:1443461-21-9 Purity >=98%

Description: GSK2838232, a betulin derivative, is a novel and potent inhibitor of human immune virus (HIV) maturation that is being developed for the treatment of chronic HIV infection. Human immunodeficiency virus type 1 (HIV-1 ) leads to the contraction of acquired immune deficiency disease (AIDS). The number of cases of HIV continues to rise, and currently over twenty-five million individuals worldwide suffer from the virus. Presently, long-term suppression of viral replication with antiretroviral drugs is the only option for treating HIV-1 infection. Indeed, the U.S. Food and Drug Administration has approved twenty-five drugs over six different inhibitor classes, which have been shown to greatly increase patient survival and quality of life. However, additional therapies are still required because of undesirable drug-drug interactions; drug-food interactions; non-adherence to therapy; and drug resistance due to mutation of the enzyme target.

References: PCT Int. Appl. (2013), WO 2013090664 A1 20130620.

-20C for 3 years in powder form

Synonym: GSK2838232; GSK-2838232; GSK 2838232.
Chemical Name: 4-(((3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-((R)-2-((3-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a, 5b, 8, 8, 11a-pentamethyl-2-oxo-3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2, 2-dimethyl-4-oxobutanoic acid.
InChi Key: DSNMRZSQABDJDK-PZFKGGKESA-N
InChi Code: InChI=1S/C48H73ClN2O6/c1-30(2)40-34(52)26-48(37(53)29-51(24-23-50(10)11)28-31-13-12-14-32(49)25-31)22-21-46(8)33(41(40)48)15-16-36-45(7)19-18-38(57-39(54)27-43(3, 4)42(55)56)44(5, 6)35(45)17-20-47(36, 46)9/h12-14, 25, 30, 33, 35-38, 53H, 15-24, 26-29H2, 1-11H3, (H, 55, 56)/t33-, 35+, 36-, 37+, 38+, 45+, 46-, 47-, 48+/m1/s1
SMILES Code: O=C(C1)C(C(C)C)=C2[C]1([CH](O)CN(CCN(C)C)CC3=CC=CC(Cl)=C3)CC[C]4(C)[C]2([H])CC[C]5([H])[C]4(C)CC[C]6([H])[C]5(C)CC[CH](OC(CC(C)(C)C(O)=O)=O)C6(C)C